Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ia, Multicenter, Open and Dose-increasing Study of DP303c to Evaluate the Safety , Pharmacokinetics, Immunogenicity and Antitumor Activity of Subjects With HER2-Positive Advanced Solid Tumors

Next Previous
Trial Profile

A Phase Ia, Multicenter, Open and Dose-increasing Study of DP303c to Evaluate the Safety , Pharmacokinetics, Immunogenicity and Antitumor Activity of Subjects With HER2-Positive Advanced Solid Tumors

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 05 Dec 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs DP 303c (Primary)
  • Indications Advanced breast cancer; Colorectal cancer; Gastric cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors CSPC ZhongQi Pharmaceutical Technology

Most Recent Events

  • 24 Oct 2023 Results (As of 28 Feb 2023, n=94) assessing safety and efficacy of DP303c in patients with HER2-positive pre-treated advanced solid tumors, presented at the 48th European Society for Medical Oncology Congress.
  • 24 Oct 2023 Status changed from not yet recruiting to recruiting, according to results presented at the 48th European Society for Medical Oncology Congress.
  • 07 Nov 2019 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top